1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: Structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain

Journal of Medicinal Chemistry

Volumn 53, Issue 19, 2010, Pages 7067-7075

  Rose, Tristan E ^a   Morisseau, Christophe ^a   Liu, Jun Yan ^a   Inceoglu, Bora ^a   Jones, Paul D ^a   Sanborn, James R ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 (CYCLOPROPANECARBONYL)PIPERIDIN 4 YL) 3 (4 (TRIFLUOROMETHOXY)PHENYL)UREA; 1 (1 ADAMANTYL) 3 (1 PROPIONYLPIPERIDIN 4 YL)UREA; 1 ARYL 3 (1 ACYLPIPERIDIN 4 YL)UREA; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; MORPHINE; UNCLASSIFIED DRUG; ADAMANTANE; CARRAGEENAN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; UREA;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; HYPERALGESIA; IN VIVO STUDY; INFLAMMATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PAIN; PHARMACOKINETICS; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; HUMAN; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT; SYNTHESIS;

ADAMANTANE; ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; EPOXIDE HYDROLASES; HUMANS; MALE; MICE; MORPHINE; PAIN; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 77957911422     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100691c     Document Type: Article

References (50)

1. Spector, A. A.; Fang, X.; Snyder, G. D.; Weintraub, N. L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function Prog. Lipid Res. 2004, 43, 55-90
2. Moghaddam, M. F.; Grant, D. F.; Cheek, J. M.; Greene, J. F.; Williamson, K. C.; Hammock, B. D. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase Nat. Med. 1997, 3, 562-566
3. Schmelzer, K. R.; Kubala, L.; Newman, J. W.; Kim, I. H.; Eiserich, J. P.; Hammock, B. D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9772-9777
4. Yu, Z. G.; Xu, F. Y.; Huse, L. M.; Morisseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids Circ. Res. 2000, 87, 992-998
5. Iliff, J. J.; Alkayed, N. J. Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent Future Neurol. 2009, 4, 179-199
6. Yousif, M. H.; Benter, I. F.; Roman, R. J. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury Auton. Autacoid. Pharmacol. 2009, 29, 33-41
7. Katragadda, D.; Batchu, S. N.; Cho, W. J.; Chaudhary, K. R.; Falck, J. R.; Seubert, J. M. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells J. Mol. Cell. Cardiol. 2009, 46, 867-875
8. Xu, D.; Li, N.; He, Y.; Timofeyev, V.; Lu, L.; Tsai, H. J.; Kim, I. H.; Tuteja, D.; Mateo, R. K. P.; Singapuri, A.; Davis, B. B.; Low, R.; Hammock, B. D.; Chiamvimonvat, N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 18733-18738
9. Morisseau, C.; Hammock, B. D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles Annu. Rev. Pharmacol. Toxicol. 2005, 45, 311-333
10. Imig, J. D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases Am. J. Physiol.: Renal Physiol. 2005, 289, 496-503
11. Chiamvimonvat, N.; Ho, C. M.; Tsai, H. J.; Hammock, B. D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension J. Cardiovasc. Pharmacol. 2007, 50, 225-237
12. Imig, J. D.; Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat. Rev. Drug Discovery 2009, 8, 794-805
13. Wang, Y-X. J.; Ulu, A.; Zhang, L.-N.; Hammock, B. D. Soluble epoxide hydrolase in atherosclerosis Curr. Atheroscler. Rep. 2010, 12, 174-183
14. Gross, G. J.; Nithipatikom, K. Soluble epoxide hydrolase: a new target for cardioprotection Curr. Opin. Invest. Drugs 2009, 10, 253-258
15. Fang, X. Soluble epoxide hydrolase: a novel target for the treatment of hypertension Recent Pat. Cardiovasc. Drug. Discovery 2006, 1, 67-72
16. Harris, T. R.; Li, N.; Chiamvimonvat, N.; Hammock, B. D. The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy Congestive Heart Failure 2008, 14, 209-224
17. Marino, J. P., Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery Curr. Top. Med. Chem. 2009, 9, 452-463
18. Shen, H. C. Soluble epoxide hydrolase inhibitors: a patent review Expert Opin Ther. Pat. 2010, 20, 941-956
19. Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8849-8854
20. Kim, I. H.; Heirtzler, F. R.; Morisseau, C.; Nishi, K.; Tsai, H. J.; Hammock, B. D. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility J. Med. Chem. 2005, 48, 3621-3629
21. Xie, Y. L.; Liu, Y. D.; Gong, G. L.; Smith, D. H.; Yan, F.; Rinderspacher, A.; Feng, Y.; Zhu, Z. X.; Li, X. P.; Deng, S. X.; Branden, L.; Vidovic, D.; Chung, C.; Schurer, S.; Morisseau, C.; Hammock, B. D.; Landry, D. W. Discovery of potent non-urea inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2009, 19, 2354-2359
22. Eldrup, A. B.; Soleymanzadeh, F.; Taylor, S. J.; Muegge, I.; Farrow, N. A.; Joseph, D.; McKellop, K.; Man, C. C.; Kukulka, A.; De Lombaert, S. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase J. Med. Chem. 2009, 52, 5880-5895
23. Anandan, S. K.; Webb, H. K.; Do, Z. N.; Gless, R. D. Unsymmetrical non-adamantyl N, N -diaryl urea and amide inhibitors of soluble expoxide hydrolase Bioorg. Med. Chem. Lett. 2009, 19, 4259-4263
24. Liu, J. Y.; Tsai, H. J.; Hwang, S. H.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Br. J. Pharmacol. 2009, 156, 284-296
25. Tsai, H. J.; Hwang, S. H.; Morisseau, C.; Yang, J.; Jones, P. D.; Kim, I. H.; Hammock, B. D. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Eur. J. Pharm. Sci. 2010, 40, 222-238
26. McElroy, N. R.; Jurs, P. C.; Morisseau, C.; Hammock, B. D. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds J. Med. Chem. 2003, 46, 1066-1080
27. Shen, H. C.; Ding, F. X.; Deng, Q.; Xu, S.; Chen, H. S.; Tong, X.; Tong, V.; Zhang, X.; Chen, Y.; Zhou, G.; Pai, L. Y.; Alonso-Galicia, M.; Zhang, B.; Roy, S.; Tata, J. R.; Berger, J. P.; Colletti, S. L. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5314-5320
28. Shen, H. C.; Ding, F. X.; Wang, S.; Deng, Q.; Zhang, X.; Chen, Y.; Zhou, G.; Xu, S.; Chen, H. S.; Tong, X.; Tong, V.; Mitra, K.; Kumar, S.; Tsai, C.; Stevenson, A. S.; Pai, L. Y.; Alonso-Galicia, M.; Chen, X.; Soisson, S. M.; Roy, S.; Zhang, B.; Tata, J. R.; Berger, J. P.; Colletti, S. L. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement J. Med. Chem. 2009, 52, 5009-5012
29. Kowalski, J. A.; Swinamer, A. D.; Muegge, I.; Eldrup, A. B.; Kukulka, A.; Cywin, C. L.; De Lombaert, S. Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method Bioorg. Med. Chem. Lett. 2010, 20, 3703-3707
30. Eldrup, A. B.; Soleymanzadeh, F.; Farrow, N. A.; Kukulka, A.; De Lombaert, S. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2010, 20, 571-575
31. Anandan, S. K.; Do, Z. N.; Webb, H. K.; Patel, D. V.; Gless, R. D. Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1066-1070
32. Jones, P. D.; Tsai, H. J.; Do, Z. N.; Morisseau, C.; Hammock, B. D. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 2006, 16, 5212-5216 (Pubitemid 44247687)
33. Hwang, S. H.; Tsai, H. J.; Liu, J. Y.; Morisseau, C.; Hammock, B. D. Orally bioavailable potent soluble epoxide hydrolase inhibitors J. Med. Chem. 2007, 50, 3825-3840
34. Morisseau, C.; Goodrow, M. H.; Newman, J. W.; Wheelock, C. E.; Dowdy, D. L.; Hammock, B. D. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases Biochem. Pharmacol. 2002, 63, 1599-1608
35. Nowick, J. S.; Holmes, D. L.; Noronha, G.; Smith, E. M.; Nguyen, T. M.; Huang, S. L. Synthesis of peptide isocyanates and isothiocyanates J. Org. Chem. 1996, 61, 3929-3934
36. Onishi, M.; Yoshiura, A.; Kohno, E.; Tsubata, K. A Process for Producing Perfluoroalkylaniline Derivatives. EP 1006102, June 7, 2000.
37. Sonda, S.; Kawahara, T.; Murozono, T.; Sato, N.; Asano, K.; Haga, K. Design and synthesis of orally active benzamide derivatives as potent serotonin 4 receptor agonist Bioorg. Med. Chem. 2003, 11, 4225-4234
38. Dhaon, M. K.; Olsen, R. K.; Ramasamy, K. Esterification of N-protected alpha-amino-acids with alcohol/carbodiimide/4-(dimethylamino)-pyridine. Racemization of aspartic and glutamic acid derivatives J. Org. Chem. 1982, 47, 1962-1965
39. Ren, Y.; Himmeldirk, K.; Chen, X. Synthesis and structure-activity relationship study of antidiabetic penta- O -galloyl- d -glucopyranose and its analogues J. Med. Chem. 2006, 49, 2829-2837
40. Hwang, S. H.; Morisseau, C.; Do, Z.; Hammock, B. D. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 5773-5777 (Pubitemid 44486739)
41. 1H NMR chemical shifts. Compounds 7, 12, 15, 24 - 28, 30, 32, and 33 were examined to minimize possible confounding effects on inhibitor potency, such as steric bulk, high polarity, and ortho substitution.
42. Zhong, H. Z.; Bowen, J. P. Molecular design and clinical development of VEGFR kinase inhibitors Curr. Top. Med. Chem. 2007, 7, 1379-1393
43. Liu, J.-Y.; Park, S.-H.; Morisseau, C.; Hwang, S. H.; Hammock, B. D.; Weiss, R. H. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo Mol. Cancer Ther. 2009, 8, 2193-2203
44. Ai, D.; Pang, W.; Li, N.; Xu, M.; Jones, P. D.; Yang, J.; Zhang, Y.; Chiamvimonvat, N.; Shyy, J. Y.-J.; Hammock, B. D.; Zhu, Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 564-569
45. Inceoglu, B.; Jinks, S. L.; Ulu, A.; Hegedus, C. M.; Georgi, K.; Schmelzer, K. R.; Wagner, K.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 18901-18906
46. Beetham, J. K.; Tian, T. G.; Hammock, B. D. CDNA cloning and expression of a soluble epoxide hydrolase from human liver Arch. Biochem. Biophys. 1993, 305, 197-201
47. Grant, D. F.; Storms, D. H.; Hammock, B. D. Molecular-cloning and expression of murine liver soluble epoxide hydrolase J. Biol. Chem. 1993, 268, 17628-17633
48. Wixtrom, R. N.; Silva, M. H.; Hammock, B. D. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated sepharose gels Anal. Biochem. 1988, 169, 71-80
49. Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies Anal. Biochem. 2005, 343, 66-75
50. Watanabe, T.; Schulz, D.; Morisseau, C.; Hammock, B. D. High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis Anal. Chim. Acta 2006, 559, 37-44